Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia

Thrombosis and Haemostasis

Volumn 115, Issue 6, 2016, Pages 1167-1177

  Zarrabeitia, Roberto ^b,c   Ojeda Fernandez, Luisa ^a,b   Recio, Lucia ^a   Bernabéu, Carmelo ^a,b   Parra, José A ^d   Albiñana, Virginia ^a   Botella, Luisa M ^a,b  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL SIERRALLANA   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

ALK1 protein; Bazedoxifene; ENG protein; Hereditary haemorrhagic telangiectasia; Selective estrogen receptor modulator

Indexed keywords

ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; BAZEDOXIFENE; ENDOGLIN; ENG PROTEIN, HUMAN; INDOLE DERIVATIVE; MESSENGER RNA; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ANGIOGENESIS; BLEEDING; BLOOD; CELL CULTURE; COMPLICATION; DRUG EFFECTS; DRUG MANUFACTURE; ENDOTHELIUM CELL; FEMALE; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; PILOT STUDY; RENDU OSLER WEBER DISEASE; WOUND HEALING;

ACTIVIN RECEPTORS, TYPE II; AGED; CELLS, CULTURED; ENDOGLIN; ENDOTHELIAL CELLS; FEMALE; HEMORRHAGE; HUMANS; INDOLES; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; ORPHAN DRUG PRODUCTION; PILOT PROJECTS; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84971539273     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-03-0239     Document Type: Article

References (38)

1. Shovlin CL. Hereditary haemorrhagic telangiectasia, pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203-219.
2. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia, current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97-110.
3. Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum. Genet 2009; 17: 860-871.
4. Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia, a population based study of prevalence and mortality in Danish patients. J Int Med 1999; 245: 31-39.
5. Plauchu H, de Chadarevian JP, Bideau A, et al. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297.
6. Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations, issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54: 714-729.
7. Vázquez C, Santana A, Recio L, et al. Hereditary haemorrhagic telangiectasia in Las Palmas (Canary Islands). Hematology Reports 2013; 5 (Suppl 1): 51.
8. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67.
9. Fernández-Ruiz E, St-Jacques S, Bellon T, et al. Assignment of the human Endoglin gene (END) to 9q34-->qter. Cytogenet Cell Genet 1993; 64: 204-207.
10. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Genet 1994; 8: 345-351.
11. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13: 189-195.
12. Cajal AR, Ramirez CV, Bravo NC, et al. Identification of novel variants in Argentinean patients which suffer from HHT. Hematology Reports 2013; 5 (Suppl 1): 48.
13. Cole SG, Begbie ME, Wallace GM, et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005; 42: 577-582.
14. Bayrak-Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet 2006; 140: 2155-2162.
15. Wooderchak-Donahue WL, McDonald J, et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 2013; 93: 530-537.
16. Santibañez JF, Quintanilla M, Bernabeu C. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci 2011; 121: 233-251.
17. Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R, et al. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of Raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010; 103: 525-534.
18. Albiñana V, Sanz-Rodríguez F, Recio-Poveda L, et al. Immunosuppressor FK506 increases Endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-β1 signaling in endothelial cells. Mol Pharmacol 2011; 79: 833-843.
19. Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, et al. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT), regulation of ALK-1/Endoglin pathway in endothelial cells. Thromb Haemost 2007; 97: 254-262.
20. Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. J Am Med Assoc 2012; 307: 948-955.
21. Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48: 73-87.
22. Zarrabeitia R, Albiñana V, Salcedo M, et al. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT). Curr Vasc Pharmacol 2010; 8: 473-481.
23. Miller PD, Chines AA, Christiansen C, et al. Effects of Bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008; 23: 525-535.
24. Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009; 16: 1102-1108.
25. Bergler W, Sadick H, Gotte K, et al. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 2002; 111: 222-228.
26. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1, establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 9: 683-690.
27. Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, et al. Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res 2005; 68: 235-248.
28. Lastres P, Bellon T, Cabañas C, et al. Regulated expression on human macrophages of Endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol. 1992; 22: 393-397.
29. Sanz-Rodriguez F, Fernandez-L A, Zarrabeitia R, et al. Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia, deficient Endoglin up-regulation in activated monocytes. Clin Chem 2004; 279: 2003-2011.
30. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-828.
31. Harvey JA, Holm MK, Ranganath R, et al. The effects of Bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 2009; 16: 1193-1196.
32. Chandrasekaran A, McKeand WE, Sullivan P, et al. Metabolic disposition of (14C)Bazedoxifene in healthy postmenopausal women. Drug Metab Dispos 2009; 37: 1219-1225.
33. Shao ES, Lin L, Yao Y, et al. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 2009; 114: 2197-2206.
34. Tual-Chalot S, Oh SP, Arthur HM. Mouse models of hereditary hemorrhagic telangiectasia: recent advances and future challenges. Front Genet 2015; 6: 25.
35. Botella LM, Albiñana V, Ojeda-Fernandez L, et al. Research on potential biomarkers in hereditary hemorrhagic telangiectasia. Front Genet 2015; 6: 115.
36. Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, et al. Gene expression fingerprinting for human hereditary hemorrhagic telangiectasia. Hum Mol Genet 2007; 16: 1515-1533.
37. David L, Mallet C, Keramidas M, et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 2008; 102: 914-922.
38. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010; 126: 5-11.